Literature DB >> 15247135

Parental exposure to medications and hydrocarbons and ras mutations in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Xiao Ou Shu1, John P Perentesis, Wanqing Wen, Jonathan D Buckley, Evelyn Boyle, Julie A Ross, Leslie L Robison.   

Abstract

Ras proto-oncogene mutations have been implicated in the pathogenesis of many malignancies, including leukemia. While both human and animal studies have linked several chemical carcinogens to specific ras mutations, little data exist regarding the association of ras mutations with parental exposures and risk of childhood leukemia. Using data from a large case-control study of childhood acute lymphoblastic leukemia (ALL; age <15 years) conducted by the Children's Cancer Group, we used a case-case comparison approach to examine whether reported parental exposure to hydrocarbons at work or use of specific medications are related to ras gene mutations in the leukemia cells of children with ALL. DNA was extracted from archived bone marrow slides or cryopreserved marrow samples for 837 ALL cases. We examined mutations in K-ras and N-ras genes at codons 12, 13, and 61 by PCR and allele-specific oligonucleotide hybridization and confirmed them by DNA sequencing. We interviewed mothers and, if available, fathers by telephone to collect exposure information. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from logistic regression to examine the association of parental exposures with ras mutations. A total of 127 (15.2%) cases had ras mutations (K-ras 4.7% and N-ras 10.68%). Both maternal (OR 3.2, 95% CI 1.7-6.1) and paternal (OR 2.0, 95% CI 1.1-3.7) reported use of mind-altering drugs were associated with N-ras mutations. Paternal use of amphetamines or diet pills was associated with N-ras mutations (OR 4.1, 95% CI 1.1-15.0); no association was observed with maternal use. Maternal exposure to solvents (OR 3.1, 95% CI 1.0-9.7) and plastic materials (OR 6.9, 95% CI 1.2-39.7) during pregnancy and plastic materials after pregnancy (OR 8.3, 95% CI 1.4-48.8) were related to K-ras mutation. Maternal ever exposure to oil and coal products before case diagnosis (OR 2.3, 95% CI 1.1-4.8) and during the postnatal period (OR 2.2, 95% CI 1.0-5.5) and paternal exposure to plastic materials before index pregnancy (OR 2.4, 95% CI 1.1-5.1) and other hydrocarbons during the postnatal period (OR 1.8, 95% CI 1.0-1.3) were associated with N-ras mutations. This study suggests that parental exposure to specific chemicals may be associated with distinct ras mutations in children who develop ALL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247135

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  16 in total

1.  Parental occupational exposure to diesel engine exhaust in relation to childhood leukaemia and central nervous system cancers: a register-based nested case-control study in Denmark 1968-2016.

Authors:  Julie Volk; Julia E Heck; Kjeld Schmiegelow; Johnni Hansen
Journal:  Occup Environ Med       Date:  2019-11       Impact factor: 4.402

Review 2.  Residential traffic exposure and childhood leukemia: a systematic review and meta-analysis.

Authors:  Vickie L Boothe; Tegan K Boehmer; Arthur M Wendel; Fuyuen Y Yip
Journal:  Am J Prev Med       Date:  2014-04       Impact factor: 5.043

3.  Tobacco Smoke and Ras Mutations Among Latino and Non-Latino Children with Acute Lymphoblastic Leukemia.

Authors:  Maneet Kaur; Adam J de Smith; Steve Selvin; Luoping Zhang; Marc Cunningham; Michelle W Kang; Helen M Hansen; Robert M Cooper; Roberta McKean-Cowdin; Joseph L Wiemels; Catherine Metayer
Journal:  Arch Med Res       Date:  2016-11       Impact factor: 2.235

4.  Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia.

Authors:  Joseph L Wiemels; Michelle Kang; Jeffrey S Chang; Lily Zheng; Carina Kouyoumji; Luoping Zhang; Martyn T Smith; Ghislaine Scelo; Catherine Metayer; Patricia Buffler; John K Wiencke
Journal:  Blood Cells Mol Dis       Date:  2010-08-05       Impact factor: 3.039

Review 5.  Is There Etiologic Heterogeneity between Subtypes of Childhood Acute Lymphoblastic Leukemia? A Review of Variation in Risk by Subtype.

Authors:  Lindsay A Williams; Jun J Yang; Betsy A Hirsch; Erin L Marcotte; Logan G Spector
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-02-15       Impact factor: 4.254

6.  Identifying efficacious approaches to chemoprevention with chlorophyllin, purified chlorophylls and freeze-dried spinach in a mouse model of transplacental carcinogenesis.

Authors:  David J Castro; Christiane V Löhr; Kay A Fischer; Katrina M Waters; Bobbie-Jo M Webb-Robertson; Roderick H Dashwood; George S Bailey; David E Williams
Journal:  Carcinogenesis       Date:  2008-12-10       Impact factor: 4.944

7.  Fetal mouse Cyp1b1 and transplacental carcinogenesis from maternal exposure to dibenzo(a,l)pyrene.

Authors:  David J Castro; William M Baird; Clifford B Pereira; Jack Giovanini; Christiane V Löhr; Kay A Fischer; Zhen Yu; Frank J Gonzalez; Sharon K Krueger; David E Williams
Journal:  Cancer Prev Res (Phila)       Date:  2008-03-19

8.  ARID5B and IKZF1 variants, selected demographic factors, and childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Amy M Linabery; Crystal N Blommer; Logan G Spector; Stella M Davies; Leslie L Robison; Julie A Ross
Journal:  Leuk Res       Date:  2013-05-18       Impact factor: 3.156

9.  Differential roles of Kras and Pten in murine leukemogenesis.

Authors:  P Tang; C Gao; A Li; J Aster; L Sun; L Chai
Journal:  Leukemia       Date:  2012-11-07       Impact factor: 11.528

10.  The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations.

Authors:  Chan Kwon Jung; Mark P Little; Jay H Lubin; Alina V Brenner; Samuel A Wells; Alice J Sigurdson; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2013-11-18       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.